Assessment of efficacy and safety of ezetimibe in patients with dyslipidemia complicated insulin resistance.
Not Applicable
- Conditions
- Dyslipidemia complicated insulin resistance
- Registration Number
- JPRN-UMIN000005775
- Lead Sponsor
- The Department of Diabetes, Endocrinology and Metabolism, Tokyo Medical University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 47
Inclusion Criteria
Not provided
Exclusion Criteria
1)HbA1c>=8% 2)Patients with anamnesis for anaphylaxis of ezetimibe tablets 3)Complicated with Severe renal and/or hepatic disease 4)Having anamnesis of myocardial infarction, angina and/or stroke 5)Patients with secondary hyperlipidemia or drug-associated hyperlipidemia 6)Patients who are pregnant or lactating women and women suspected of being pregnant 7)Patients of Familial hyperlipidemia 8)Other patients deemed not appropriate for study entry by the investigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1)Flow Mediated Dilation test 2)Volume of visceral fat and fatty liver) 3)Improvement ratio of Cholesterol Absorption and Synthesis Markers 4)Improvement ratio of Oxidized low density lipoprotein and Atherogenic lipoprotein level 3)
- Secondary Outcome Measures
Name Time Method 1)Improvement ratio of glucose metabolism makers 2)Improvement of inflammatory makers and Oxidation makers